Development of an orthotopic canine prostate cancer model expressing human GRPr.
Michael F TweedleHaiming DingWilliam T DrostJoshua DowellJames SpainMathew JosephSaid M ElshafaeMaria-Isabela MenendezLi GongShankaran KothandaramanWessel P DirksenChadwick L WrightRobert BahnsonMichael V KnoppThomas J RosolPublished in: The Prostate (2018)
Ace-1huGRPr cells created viable, huGRPr-expressing tumors when implanted orthotopically into immune-suppressed dogs. Local delivery of an imaging agent through the prostatic artery allowed a very low imaging dose, suggesting that therapeutic agents could be used safely for treatment of early localized intraglandular prostate cancer as adjuvant therapy for active surveillance or focal ablation therapies, or for treating multifocal intraglandular disease where focal ablation therapies are not indicated or ineffective.
Keyphrases
- prostate cancer
- radical prostatectomy
- high resolution
- induced apoptosis
- endothelial cells
- early stage
- cell cycle arrest
- radiofrequency ablation
- cell death
- angiotensin ii
- oxidative stress
- signaling pathway
- induced pluripotent stem cells
- combination therapy
- photodynamic therapy
- pluripotent stem cells
- cell proliferation
- wild type
- replacement therapy
- benign prostatic hyperplasia